PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib

Sorafenib is currently the only systemic agent approved for treatment of advanced hepatocellular carcinoma (HCC). However, intrinsic and acquired resistance to sorafenib remains a great challenge with respect to improving the prognoses of patients with HCC. The cyto-protective functions of autophagy...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Death Dis
Autori principali: Zhang, Kai, Chen, Jing, Zhou, Hao, Chen, Ying, Zhi, Yingru, Zhang, Bei, Chen, Longbang, Chu, Xiaoyuan, Wang, Rui, Zhang, Chunni
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833744/
https://ncbi.nlm.nih.gov/pubmed/29472524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0344-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi